Personalized genomic medicine

Novelli, Giuseppe

doi:10.1007/s11739-010-0455-9

Cited by 18 publications

(13 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The medical doctors, medical professional groups have identified a long back that each patient is unique. Subsequently, medical societies started speaking for many decades that it is documented the prevalence of similar diseases within close relatives and ethnic groups, a range of different drug responses with adverse effects, and various signs and symptoms often observed with the same pathological condition [8][9][10][11] . Although some notion of personalized medicine exists nearing 60 years, it first appeared in 1999 in a published manuscript [12][13][14] .…”

Section: B a Brief History Of Pmmentioning

confidence: 99%

Prospects and Challenges of Precision Medicine in Lower- and Middle-Income Countries: A Brief Overview

Haque

Islam

Sartelli

et al. 2019

Bangladesh J Med Sci

View full text Add to dashboard Cite

The trend of NCDs in most LMIC countries is slowly but gradually follows that of in the developed countries. There are four significant diseases reported by WHO, which are equally common, such as CVDs, diabetes, cancer, and chronic respiratory disease that causes widespread early death & morbidity. Indeed, it incurs an overwhelming financial burden to most countries in the world. The rise of drug-resistant microbes is another major problem. To overcome this issue, precision medicine (PM) comes into play whereby individual variability in genes, environment, lifestyle, and nutrition of each person is considered for disease treatment & prevention. PM provides a personalized approach, the right treatment to the right people at the right time. Many wealthy countries in the West have started adopting PM though the initial cost is high, ultimately, in the long run, will reduce the healthcare cost by getting rid of the ineffective treatment strategies. However, the PM in LMICs is still at an early stage due to issues such as lack of populationspecific data, competency, expertise, and poor financial support. Bangladesh Journal of Medical Science Vol.19(1) 2020 p.32-47

show abstract

Section: B a Brief History Of Pmmentioning

confidence: 99%

Prospects and Challenges of Precision Medicine in Lower- and Middle-Income Countries: A Brief Overview

Haque

Islam

Sartelli

et al. 2019

Bangladesh J Med Sci

View full text Add to dashboard Cite

show abstract

Section: The Age Of Precision Medicinementioning

confidence: 99%

“…This allowed for two key discoveries that have led to the age of genomic medicine; single nucleotide polymorphism (SNP) and the microarray analysis used to detect them [2,3]. SNPs account for about 90% of known genetic polymorphisms in the 0.9% of our genome that makes each individual unique [2]. Characterization of SNPs in variegated pathologies and treatment success have associated different molecular signatures with the diagnosis, prognosis, and therapy given to individual patients.…”

Section: The Age Of Precision Medicinementioning

confidence: 99%

Personalized Proteomics: The Future of Precision Medicine

2016

View full text Add to dashboard Cite

Medical diagnostics and treatment has advanced from a one size fits all science to treatment of the patient as a unique individual. Currently, this is limited solely to genetic analysis. However, epigenetic, transcriptional, proteomic, posttranslational modifications, metabolic, and environmental factors influence a patient’s response to disease and treatment. As more analytical and diagnostic techniques are incorporated into medical practice, the personalized medicine initiative transitions to precision medicine giving a holistic view of the patient’s condition. The high accuracy and sensitivity of mass spectrometric analysis of proteomes is well suited for the incorporation of proteomics into precision medicine. This review begins with an overview of the advance to precision medicine and the current state of the art in technology and instrumentation for mass spectrometry analysis. Thereafter, it focuses on the benefits and potential uses for personalized proteomic analysis in the diagnostic and treatment of individual patients. In conclusion, it calls for a synthesis between basic science and clinical researchers with practicing clinicians to design proteomic studies to generate meaningful and applicable translational medicine. As clinical proteomics is just beginning to come out of its infancy, this overview is provided for the new initiate.

show abstract

“…The successful mapping of the entire human genome revealed that though human genetic make-up is 99.1% identical, a small 0.9% inter-individual genetic difference causes a wide variability in physical and mental phenotypes among the human subjects. [ 16 ] This genomic variability may determine all variable health-related properties and behaviors among the people. The fact that response to a drug is different in every person or most of the diseases show variable manifestation in the bodies compared with each other proves PM medical model.…”

Section: Novel Personalized Medicinementioning

confidence: 99%

“…[ 18 ] SNPs are frequent single nucleotide changes in the DNA sequence which are predominantly common in the population, including 90% of all known polymorphisms. [ 16 18 19 ] Detection of these polymorphisms is essential to determine patient predisposition to various diseases and drug therapy responsiveness.…”

Section: Novel Personalized Medicinementioning

confidence: 99%